Using an established CRISPR-Cas mediated genome editing technique for streptomycetes, we 4 explored the combinatorial biosynthesis potential of the auroramycin biosynthetic gene cluster in 5 Streptomyces roseoporous. Auroramycin is a potent anti-MRSA polyene macrolactam. In addition, it 6 also displays antifungal activities, which is unique among structurally similar polyene macrolactams, 7 such as incednine and silvalactam. In this work, we employed different engineering strategies to target 8 glycosylation and acylation biosynthetic machineries within its recently elucidated biosynthetic pathway.
Introduction 18
Natural products (NPs) are an important source for pharmacological applications with a significant 
3
Based on these observations, we proposed the following scheme for glycosylation in the auroramycin 4 biosynthetic pathway: xylosamine is first glycosylated by AurS4 and AurS5, after which, 3, 5-epi-5 lemonose is added by AurS12 and AurS13 with AurS10 needed for increased efficiency of the second 6 glycosylation step ( Figure 3C, D) . Notably, contrary to in silico predictions that the truncated gene 
22
With Dszs AT complementation of inactive AT10 (AT10°), instead of obtaining only the malonyl moiety 23 incorporated compound (8, Figure 4D ), we also found the mmCoA analog 9. Analogs 8 and 9 were 24 produced at an approximately 1:2 ratio and with yields less than 5% of auroramycin. Substrate 25 preference of Dszs AT for mCoA to mmCoA was observed previously to be approximately more than 
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Conservation of this functional group suggests that either hydroxylation or/and methylation at this site 13 might be important for bioactivity. To investigate the role of the additional hydroxyl group at C-10, we 14 examined the production of dehydroxylated analog 10. In the aurO1 deletion mutant, only production of 
